Skip to main content
ZLAB
NASDAQ Life Sciences

Shareholders Approve 10% Share Issuance and Repurchase Mandates

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$17.88
Mkt Cap
$2.017B
52W Low
$15.96
52W High
$41.2
52W Position info
12% above low
Off High info
57% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

ZLAB is trading near its 52-week low of $15.96 (12% above the low).

Summary

Zai Lab shareholders approved mandates for the Board to issue and repurchase up to 10% of the company's shares, providing significant capital management flexibility.


Key Events · Corporate Governance and Compliance · ZLAB

  • Share Issuance Mandate Approved

    Shareholders authorized the Board to allot and issue up to 10% of the company's total issued ordinary shares and/or American Depositary Shares (ADSs).

  • Share Repurchase Mandate Approved

    Shareholders authorized the Board to repurchase up to 10% of the company's total issued ordinary shares and/or ADSs.

  • Director Re-elections

    All nine proposed directors, including CEO Samantha Du, were re-elected to serve until the 2027 annual general meeting.

  • Auditor Appointment Approved

    KPMG LLP and KPMG were approved as the company's independent registered public accounting firms and auditors for the year ending December 31, 2026.


Analysis · ZLAB · Life Sciences

Zai Lab shareholders approved mandates allowing the Board to issue and repurchase up to 10% of outstanding shares. This grants the company significant flexibility in managing its capital structure, which is particularly relevant given recent financial results and ongoing R&D needs. The issuance mandate provides a mechanism for future capital raises, while the repurchase mandate offers a tool for returning value to shareholders or offsetting dilution.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ZLAB was trading at $17.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $15.96 to $41.20. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ZLAB - Latest Insights

ZLAB
Nov 13, 2026, 10:26 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $24.60
Real-time Price: $23.53 info
Change: -$1.07 (-4%) info
Market Cap: $3.07B info
ZLAB
Nov 05, 2026, 9:00 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $23.19
Real-time Price: $23.53 info
Change: +$0.340 (+1%) info
Market Cap: $3.07B info
ZLAB
Nov 05, 2026, 6:41 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $23.19
Real-time Price: $23.53 info
Change: +$0.340 (+1%) info
Market Cap: $3.07B info
ZLAB
Nov 05, 2026, 6:30 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $23.19
Real-time Price: $23.53 info
Change: +$0.340 (+1%) info
Market Cap: $3.07B info
ZLAB
Oct 23, 2026, 6:33 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $22.87
Real-time Price: $23.53 info
Change: +$0.660 (+3%) info
Market Cap: $3.07B info